Dorothée Ville
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dorothée Ville has a total of 450 co-authors. Here are the top co-authors by number of shared publications:
- Gaetan Lesca
Department of Medical Genetics, University Hospital of Lyon, Claude Bernard University Lyon 1, Lyon, France
13 shared publications - Nicolas Chatron
Genetics Department, Hospices Civils de Lyon, Lyon, France
6 shared publications - Anna Kaminska
APHP, Department of Clinical Neurophysiology, Necker-Enfants Malades Hospital, Paris, France
5 shared publications - Vincent Des Portes
Centre de Référence “Déficiences Intellectuelles de causes rares”, Hospices Civils de Lyon, Université Lyon 1 , Bron 69500
5 shared publications - Catherine Chiron
Necker-Enfants Malades Hospital
4 shared publications - Mathieu Milh
CHU Timone, APHM, Centre de Référence Maladies Rares Anomalies du Développement et Syndromes malformatifs, Marseille, France
4 shared publications
Latest Publications
- Open Access
Long-read genome sequencing resolves complex structural variants in exome-negative developmental and epileptic encephalopathy
Background and Objectives: Developmental and Epileptic Encephalopathies (DEEs) encompass a clinically and molecularly heterogeneous group of mainly genetic disorders. Despite standard genetic testing, approximately two-thirds of patients remain undiagnosed. Pathogenic noncoding and structural variants (SVs), particularly complex rearrangements that are difficult to detect or resolve using short-read sequencing, may contribute to this diagnostic gap. To evaluate the diagnostic contribution of long-read genome sequencing (lrGS), we recruited a cohort of 124 families with sporadic DEE who remained unsolved by prior ES. Methods: Trio lrGS (Oxford Nanopore or PacBio HiFi) was performed, complemented zby short-read genome sequencing (srGS) and mRNA sequencing (blood or fibroblast) of index cases, where available. Comprehensive variant analysis included small nucleotide variants (SNVs), indels, SVs, and short tandem repeats. To identify the diagnostic yield of each method, we compared lrGS, srGS and ES re-analysis, and evaluated the additional value of RNA sequencing. Results: We established a diagnosis in 21 of 124 families (16.9%). Fourteen variants were retrospectively detectable in prior ES., Two cases with non-coding variants in SCN1A and RNU2-2 were detectable by both srGS and lrGS. Five SVs also required genome sequencing (5.6% of the total cohort), three of which could be detected, but not confidently resolved by srGS due to breakpoint complexity, repeat-mediated rearrangements, and large copy-neutral events: LrGS enabled accurate characterization of Alu-mediated CDKL5 and STXBP1 deletions and a MEF2C deletion with large inversion. A copy-neutral SCN1A inversion was well characterizable by both srGS and lrGS. One balanced translocation t(X;17) disrupting CDKL5 was resolved by lrGS (srGS unavailable). RNA sequencing confirmed pathogenicity of two SVs including t(X;17), the MEF2C deletion with inversion, and two CNVs. In addition, ZNF569 and ZNF570 emerged as candidate epilepsy genes from our cohort. Discussion: In ES-negative DEE, the incremental diagnostic yield of genome sequencing was modest, while lrGS provided particular value for the structural resolution of complex rearrangements, especially those involving repetitive sequences. The finding that two-thirds of diagnoses were retrospectively detectable in prior ES highlights the substantial value of systematic reanalysis. Further gains from genome sequencing may increasingly depend on improved interpretation of non-coding variation and integration of long-read-specific information. Our findings indicate that complex SVs represent the class for which lrGS currently yields the most distinctive diagnostic information.
Open AccessLong-read genome sequencing resolves complex structural variants in exome-negative developmental and epileptic encephalopathy
Background and Objectives: Developmental and Epileptic Encephalopathies (DEEs) encompass a clinically and molecularly heterogeneous group of mainly genetic disorders. Despite standard genetic testing, approximately two-thirds of patients remain undiagnosed. Pathogenic noncoding and structural variants (SVs), particularly complex rearrangements that are difficult to detect or resolve using short-read sequencing, may contribute to this diagnostic gap. To evaluate the diagnostic contribution of long-read genome sequencing (lrGS), we recruited a cohort of 124 families with sporadic DEE who remained unsolved by prior ES. Methods: Trio lrGS (Oxford Nanopore or PacBio HiFi) was performed, complemented zby short-read genome sequencing (srGS) and mRNA sequencing (blood or fibroblast) of index cases, where available. Comprehensive variant analysis included small nucleotide variants (SNVs), indels, SVs, and short tandem repeats. To identify the diagnostic yield of each method, we compared lrGS, srGS and ES re-analysis, and evaluated the additional value of RNA sequencing. Results: We established a diagnosis in 21 of 124 families (16.9%). Fourteen variants were retrospectively detectable in prior ES., Two cases with non-coding variants in SCN1A and RNU2-2 were detectable by both srGS and lrGS. Five SVs also required genome sequencing (5.6% of the total cohort), three of which could be detected, but not confidently resolved by srGS due to breakpoint complexity, repeat-mediated rearrangements, and large copy-neutral events: LrGS enabled accurate characterization of Alu-mediated CDKL5 and STXBP1 deletions and a MEF2C deletion with large inversion. A copy-neutral SCN1A inversion was well characterizable by both srGS and lrGS. One balanced translocation t(X;17) disrupting CDKL5 was resolved by lrGS (srGS unavailable). RNA sequencing confirmed pathogenicity of two SVs including t(X;17), the MEF2C deletion with inversion, and two CNVs. In addition, ZNF569 and ZNF570 emerged as candidate epilepsy genes from our cohort. Discussion: In ES-negative DEE, the incremental diagnostic yield of genome sequencing was modest, while lrGS provided particular value for the structural resolution of complex rearrangements, especially those involving repetitive sequences. The finding that two-thirds of diagnoses were retrospectively detectable in prior ES highlights the substantial value of systematic reanalysis. Further gains from genome sequencing may increasingly depend on improved interpretation of non-coding variation and integration of long-read-specific information. Our findings indicate that complex SVs represent the class for which lrGS currently yields the most distinctive diagnostic information.
- 23 June 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (12) , e218013
Burst-Suppression EEG in Early Infantile Developmental and Epileptic Encephalopathies
Background and ObjectivesDevelopmental and epileptic encephalopathies (DEEs) with early burst-suppression EEG (EIDEE-BS) are among the most severe neonatal epileptic syndromes, typically presenting...
- 23 June 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (12) , e218013
Burst-Suppression EEG in Early Infantile Developmental and Epileptic Encephalopathies
Background and ObjectivesDevelopmental and epileptic encephalopathies (DEEs) with early burst-suppression EEG (EIDEE-BS) are among the most severe neonatal epileptic syndromes, typically presenting...
- Open Access
Compound heterozygous SLC12A5 variants expand the molecular and functional spectrum of KCC2 ‐developmental and epileptic encephalopathy
Objective: This study was undertaken to characterize the functional impact of novel SLC12A5 variants in two unrelated patients with early onset developmental and epileptic encephalopathy (DEE) and to investigate the mechanisms underlying KCC2 dysfunction. Methods: Clinical, genetic, and functional analyses were performed in two patients (Cases A and B) with DEE. SLC12A5 encodes two KCC2 splice isoforms (KCC2a and KCC2b). Functional effects of the identified variants on KCC2b ion transport, phosphorylation, mRNA processing, and KCC2‐dependent synaptogenesis were assessed using in vitro assays in heterologous expression systems and primary neurons, supported by in silico structural modeling. Results: Both patients developed severe neonatal onset DEE characterized by developmental delay, axial hypotonia, extrapyramidal features, and bilateral migratory seizures within 24 h of birth. Both cases resulted in early mortality (Case A at 9 years; Case B at 6 months). Sequencing revealed distinct biallelic compound heterozygous SLC12A5 variants in both individuals, each inherited from one unaffected parent. Functional analyses demonstrated that in Case A, one variant markedly reduced KCC2‐mediated ion transport, whereas the second variant preserved transport activity but exhibited an altered phosphorylation profile at Ser940, located on the intracellular C ‐terminal region. This variant also disrupted wild‐type (WT) KCC2‐dependent excitatory synapse formation in immature rat hippocampal neurons. In Case B, one variant disrupted normal mRNA transcript processing consistent with loss of expression, and the second variant exhibited reduced ion transport activity. Significance: These data demonstrate that SLC12A5 ‐related DEE can result from combined impairment of KCC2‐dependent chloride homeostasis and disruption of chloride‐independent KCC2 functions critical for early neuronal development. This work expands the mutational and mechanistic spectrum of SLC12A5 ‐DEE and highlights the importance of KCC2 regulatory roles in early brain development, providing new knowledge and tools for basic research and potential avenues for targeted precision therapies.
Open AccessCompound heterozygous SLC12A5 variants expand the molecular and functional spectrum of KCC2 ‐developmental and epileptic encephalopathy
Objective: This study was undertaken to characterize the functional impact of novel SLC12A5 variants in two unrelated patients with early onset developmental and epileptic encephalopathy (DEE) and to investigate the mechanisms underlying KCC2 dysfunction. Methods: Clinical, genetic, and functional analyses were performed in two patients (Cases A and B) with DEE. SLC12A5 encodes two KCC2 splice isoforms (KCC2a and KCC2b). Functional effects of the identified variants on KCC2b ion transport, phosphorylation, mRNA processing, and KCC2‐dependent synaptogenesis were assessed using in vitro assays in heterologous expression systems and primary neurons, supported by in silico structural modeling. Results: Both patients developed severe neonatal onset DEE characterized by developmental delay, axial hypotonia, extrapyramidal features, and bilateral migratory seizures within 24 h of birth. Both cases resulted in early mortality (Case A at 9 years; Case B at 6 months). Sequencing revealed distinct biallelic compound heterozygous SLC12A5 variants in both individuals, each inherited from one unaffected parent. Functional analyses demonstrated that in Case A, one variant markedly reduced KCC2‐mediated ion transport, whereas the second variant preserved transport activity but exhibited an altered phosphorylation profile at Ser940, located on the intracellular C ‐terminal region. This variant also disrupted wild‐type (WT) KCC2‐dependent excitatory synapse formation in immature rat hippocampal neurons. In Case B, one variant disrupted normal mRNA transcript processing consistent with loss of expression, and the second variant exhibited reduced ion transport activity. Significance: These data demonstrate that SLC12A5 ‐related DEE can result from combined impairment of KCC2‐dependent chloride homeostasis and disruption of chloride‐independent KCC2 functions critical for early neuronal development. This work expands the mutational and mechanistic spectrum of SLC12A5 ‐DEE and highlights the importance of KCC2 regulatory roles in early brain development, providing new knowledge and tools for basic research and potential avenues for targeted precision therapies.
- Open Access
- 20 February 2026
- Published by Wiley in Prenatal Diagnosis
- Vol. 46 (3) , 315-328
Prenatal Diagnosis and Neurodevelopmental Outcome of Children With Marked Opening of the Fourth Ventricle: Challenges and Pitfalls in MRI Diagnostic Criteria
Introduction: The neurodevelopmental outcome of ‘Cystic’ malformations of the posterior fossa with marked opening of the fourth ventricle, such as Dandy Walker malformation (DWM) and large Blake's pouch cyst (BPC), is a major issue. This study aimed to refine relevant MRI criteria for distinguishing DWM from BPC and identify prognostic factors. Patients and Methods: Inclusion criteria were prenatal retrocerebellar fluid space diameter > 10 mm, marked opening of the fourth ventricle with a tegmento‐vermian angle (TVA) > 40°, and postnatal follow‐up > 2 years. Results: 27 patients were classified as follows: 6 DWM characterized by an overall upward orientation of the tentorium, an open tegmento‐tentorial angle (TTA > 78 ) and a high TVA (median 132°); 15 BPC with a normal downward orientation of the proximal part of the tentorium (TTA < 68°) and distal upward displacement (median TVA 74°); 3 PHACE syndromes (Posterior fossa abnormalities, Haemangioma, Arterial cerebrovascular anomalies, Cardiac defects, Eye anomalies) and 3 unclassified. Four prognostic factors were identified, (i) diagnosis: DWM (two deaths, three learning disabilities and one typical development (TD)) versus BPC (five learning disabilities [4/5 with associated malformation or genetic defects] and 10 TD); (ii) associated versus isolated (36% vs. 87% TD); (iii) obstructive ventriculomegaly versus no hydraulic complications (20% vs. 91% TD); and (iv) the foetal TVA value and clinical outcome (correlation coefficient = 0.561, p = 0.006).
- 20 February 2026
- Published by Wiley in Prenatal Diagnosis
- Vol. 46 (3) , 315-328
Open AccessPrenatal Diagnosis and Neurodevelopmental Outcome of Children With Marked Opening of the Fourth Ventricle: Challenges and Pitfalls in MRI Diagnostic Criteria
Introduction: The neurodevelopmental outcome of ‘Cystic’ malformations of the posterior fossa with marked opening of the fourth ventricle, such as Dandy Walker malformation (DWM) and large Blake's pouch cyst (BPC), is a major issue. This study aimed to refine relevant MRI criteria for distinguishing DWM from BPC and identify prognostic factors. Patients and Methods: Inclusion criteria were prenatal retrocerebellar fluid space diameter > 10 mm, marked opening of the fourth ventricle with a tegmento‐vermian angle (TVA) > 40°, and postnatal follow‐up > 2 years. Results: 27 patients were classified as follows: 6 DWM characterized by an overall upward orientation of the tentorium, an open tegmento‐tentorial angle (TTA > 78 ) and a high TVA (median 132°); 15 BPC with a normal downward orientation of the proximal part of the tentorium (TTA < 68°) and distal upward displacement (median TVA 74°); 3 PHACE syndromes (Posterior fossa abnormalities, Haemangioma, Arterial cerebrovascular anomalies, Cardiac defects, Eye anomalies) and 3 unclassified. Four prognostic factors were identified, (i) diagnosis: DWM (two deaths, three learning disabilities and one typical development (TD)) versus BPC (five learning disabilities [4/5 with associated malformation or genetic defects] and 10 TD); (ii) associated versus isolated (36% vs. 87% TD); (iii) obstructive ventriculomegaly versus no hydraulic complications (20% vs. 91% TD); and (iv) the foetal TVA value and clinical outcome (correlation coefficient = 0.561, p = 0.006).
- Open Access
- 8 August 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (8) , e70324
The Clinical and Genetic Landscape of a French Multicenter Cohort of 2563 Epilepsy Patients Referred for Genetic Diagnosis
Background: Epileptic disorders are a heterogeneous group of neurological conditions, with many cases linked to monogenic causes, particularly in developmental and epileptic encephalopathies (DEE). Identifying pathogenic variants aids treatment, prognosis, and family planning. In France, genetic testing is coordinated through the EpiGene network.Methods: We analyzed clinical and genetic data from 2563 epilepsy patients referred to four diagnostic labs (2016–2023). Epilepsy syndromes were classified via pre‐test questionnaires, and genotyping used various gene panels, including a 68‐gene core panel. Multivariate logistic regression assessed diagnostic rates and genotype–phenotype correlations.Results: Overall, 27.0% of patients had pathogenic/likely pathogenic variants, mainly within the core panel (24%). SCN1A and KCNQ2 were the most frequently mutated genes. Diagnostic yield varied by syndrome, with Dravet Syndrome Spectrum (DSS) and early‐infantile DEE (EIDEE) showing the highest rates (41% and 34%, respectively). Genetic heterogeneity differed across syndromes, from DSS (predominantly SCN1A) to Infantile Epileptic Spasms Syndrome (IESS, 12%), involving ≥ 26 genes. Outside DEE, self‐limited neonatal epilepsy (SeLNE) had the highest yield (50%). Earlier seizure onset was associated with a higher likelihood of a positive molecular diagnosis, whereas intellectual disability severity and drug resistance were not independently predictive of diagnostic outcome. Genotype–phenotype correlations highlighted that objective clinical data (e.g., age of onset) can outperform syndrome labels (e.g., EIDEE) in predicting diagnosis.Conclusion: This large cohort study refines the genetic landscape of epilepsy, informs classification challenges, and enhances genetic testing strategies, ultimately improving patient care and future research directions.
- 8 August 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (8) , e70324
Open AccessThe Clinical and Genetic Landscape of a French Multicenter Cohort of 2563 Epilepsy Patients Referred for Genetic Diagnosis
Background: Epileptic disorders are a heterogeneous group of neurological conditions, with many cases linked to monogenic causes, particularly in developmental and epileptic encephalopathies (DEE). Identifying pathogenic variants aids treatment, prognosis, and family planning. In France, genetic testing is coordinated through the EpiGene network.Methods: We analyzed clinical and genetic data from 2563 epilepsy patients referred to four diagnostic labs (2016–2023). Epilepsy syndromes were classified via pre‐test questionnaires, and genotyping used various gene panels, including a 68‐gene core panel. Multivariate logistic regression assessed diagnostic rates and genotype–phenotype correlations.Results: Overall, 27.0% of patients had pathogenic/likely pathogenic variants, mainly within the core panel (24%). SCN1A and KCNQ2 were the most frequently mutated genes. Diagnostic yield varied by syndrome, with Dravet Syndrome Spectrum (DSS) and early‐infantile DEE (EIDEE) showing the highest rates (41% and 34%, respectively). Genetic heterogeneity differed across syndromes, from DSS (predominantly SCN1A) to Infantile Epileptic Spasms Syndrome (IESS, 12%), involving ≥ 26 genes. Outside DEE, self‐limited neonatal epilepsy (SeLNE) had the highest yield (50%). Earlier seizure onset was associated with a higher likelihood of a positive molecular diagnosis, whereas intellectual disability severity and drug resistance were not independently predictive of diagnostic outcome. Genotype–phenotype correlations highlighted that objective clinical data (e.g., age of onset) can outperform syndrome labels (e.g., EIDEE) in predicting diagnosis.Conclusion: This large cohort study refines the genetic landscape of epilepsy, informs classification challenges, and enhances genetic testing strategies, ultimately improving patient care and future research directions.
- Open Access
- 1 August 2024
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 10 (4) , e200168
Expanding the Mutational Landscape and Clinical Phenotype of CHD2-Related Encephalopathy
To present a case series of novel CHD2 variants in patients presenting with genetic epileptic and developmental encephalopathy. CHD2 gene encodes an ATP-dependent enzyme, chromodomain helicase DNA-binding protein 2, involved in chromatin remodeling. Pathogenic variants in CHD2 are linked to early-onset conditions such as developmental and epileptic encephalopathy, drug-resistant epilepsies, and neurodevelopmental disorders. Approximately 225 diagnosed patients from 28 countries exhibit various allelic variants in CHD2, including small intragenic deletions/insertions and missense, nonsense, and splice site variants. We present the molecular and clinical characteristics of 17 unreported individuals from 17 families with novel pathogenic or likely pathogenic variants in CHD2. All individuals presented with severe global developmental delay, childhood-onset myoclonic epilepsy, and additional neuropsychiatric features, such as behavioral including autism, ADHD, and hyperactivity. Additional findings include abnormal reflexes, hypotonia and hypertonia, motor impairment, gastrointestinal problems, and kyphoscoliosis. Neuroimaging features included hippocampal signal alterations (4/10), with additional volume loss in 2 cases, inferior vermis hypoplasia (7/10), mild cerebellar atrophy (4/10), and cerebral atrophy (1/10). Our study broadens the geographic scope of CHD2-related phenotypes, providing valuable insights into the prevalence and clinical characteristics of this genetic disorder in previously underrepresented populations.
- 1 August 2024
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 10 (4) , e200168
Open AccessExpanding the Mutational Landscape and Clinical Phenotype of CHD2-Related Encephalopathy
To present a case series of novel CHD2 variants in patients presenting with genetic epileptic and developmental encephalopathy. CHD2 gene encodes an ATP-dependent enzyme, chromodomain helicase DNA-binding protein 2, involved in chromatin remodeling. Pathogenic variants in CHD2 are linked to early-onset conditions such as developmental and epileptic encephalopathy, drug-resistant epilepsies, and neurodevelopmental disorders. Approximately 225 diagnosed patients from 28 countries exhibit various allelic variants in CHD2, including small intragenic deletions/insertions and missense, nonsense, and splice site variants. We present the molecular and clinical characteristics of 17 unreported individuals from 17 families with novel pathogenic or likely pathogenic variants in CHD2. All individuals presented with severe global developmental delay, childhood-onset myoclonic epilepsy, and additional neuropsychiatric features, such as behavioral including autism, ADHD, and hyperactivity. Additional findings include abnormal reflexes, hypotonia and hypertonia, motor impairment, gastrointestinal problems, and kyphoscoliosis. Neuroimaging features included hippocampal signal alterations (4/10), with additional volume loss in 2 cases, inferior vermis hypoplasia (7/10), mild cerebellar atrophy (4/10), and cerebral atrophy (1/10). Our study broadens the geographic scope of CHD2-related phenotypes, providing valuable insights into the prevalence and clinical characteristics of this genetic disorder in previously underrepresented populations.
- Open Access
- 27 November 2023
- Published by Wiley in Epilepsia Open
- Vol. 9 (1) , 106-121
Electroclinical features and phenotypic differences in adenylosuccinate lyase deficiency: Long‐term follow‐up of seven patients from four families and appraisal of the literature
Objective: Adenylosuccinate lyase (ADSL) deficiency is a rare inherited metabolic disorder with a wide phenotypic presentation, classically grouped into three types (neonatal, type I, and type II). We aim to better delineate the pathological spectrum, focusing on the electroclinical characteristics and phenotypic differences of patients with ADSL deficiency.Patients and Methods: Seven patients, from four different families, underwent serial electroencephalogram (EEG), clinical assessment, and neuroimaging. We also performed a systematic review of the cases published in the literature, summarizing the available clinical, neurophysiological, and genetic data.Results: We report seven previously unreported ADSL deficiency patients with long‐term follow‐up (10–34 years). From the literature review, we collected 81 previously reported cases. Of the included patient population, 58 % (51/88) were classified as having ADSL deficiency type I, 28% (25/88) as having type II, and 14% (12/88) as having neonatal. The most frequently reported pathogenic variants are p.R426H homozygous (19 patients), p.Y114H in compound heterozygosity (13 patients), and p.D430N homozygous (6 patients). In the majority (89.2%), disease onset was within the first year of life. Epilepsy is present in 81.8% of the patients, with polymorphic and often intractable seizures. EEG features seem to display common patterns and developmental trajectories: (i) poor general background organization with theta‐delta activity; (ii) hypsarrhythmia with spasms, usually adrenocorticotropic hormone‐responsive; (iii) generalized epileptic discharges with frontal or frontal temporal predominance; and (iv) epileptic discharge activation in sleep with an altered sleep structure. Imaging features present consistent findings of cerebral atrophy with frontal predominance, cerebellar atrophy, and white matter abnormalities among the three types.Significance: ADSL deficiency presents variable phenotypic expression, whose severity could be partially attributed to residual activity of the mutant protein. Although a precise phenotype‐genotype correlation was not yet feasible, we delineated a common pattern of clinical, neuroradiological, and neurophysiological features.
- 27 November 2023
- Published by Wiley in Epilepsia Open
- Vol. 9 (1) , 106-121
Open AccessElectroclinical features and phenotypic differences in adenylosuccinate lyase deficiency: Long‐term follow‐up of seven patients from four families and appraisal of the literature
Objective: Adenylosuccinate lyase (ADSL) deficiency is a rare inherited metabolic disorder with a wide phenotypic presentation, classically grouped into three types (neonatal, type I, and type II). We aim to better delineate the pathological spectrum, focusing on the electroclinical characteristics and phenotypic differences of patients with ADSL deficiency.Patients and Methods: Seven patients, from four different families, underwent serial electroencephalogram (EEG), clinical assessment, and neuroimaging. We also performed a systematic review of the cases published in the literature, summarizing the available clinical, neurophysiological, and genetic data.Results: We report seven previously unreported ADSL deficiency patients with long‐term follow‐up (10–34 years). From the literature review, we collected 81 previously reported cases. Of the included patient population, 58 % (51/88) were classified as having ADSL deficiency type I, 28% (25/88) as having type II, and 14% (12/88) as having neonatal. The most frequently reported pathogenic variants are p.R426H homozygous (19 patients), p.Y114H in compound heterozygosity (13 patients), and p.D430N homozygous (6 patients). In the majority (89.2%), disease onset was within the first year of life. Epilepsy is present in 81.8% of the patients, with polymorphic and often intractable seizures. EEG features seem to display common patterns and developmental trajectories: (i) poor general background organization with theta‐delta activity; (ii) hypsarrhythmia with spasms, usually adrenocorticotropic hormone‐responsive; (iii) generalized epileptic discharges with frontal or frontal temporal predominance; and (iv) epileptic discharge activation in sleep with an altered sleep structure. Imaging features present consistent findings of cerebral atrophy with frontal predominance, cerebellar atrophy, and white matter abnormalities among the three types.Significance: ADSL deficiency presents variable phenotypic expression, whose severity could be partially attributed to residual activity of the mutant protein. Although a precise phenotype‐genotype correlation was not yet feasible, we delineated a common pattern of clinical, neuroradiological, and neurophysiological features.
- 20 November 2023
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 47, A1
Advances in genetics: The start of a new stage for management of focal cortical malformations
- 20 November 2023
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 47, A1
Advances in genetics: The start of a new stage for management of focal cortical malformations
- Open Access
Clinical Cases and the Molecular Profiling of a Novel Childhood Encephalopathy-Causing GNAO1 Mutation P170R
De novo mutations in GNAO1, the gene encoding the major neuronal G protein Gαo, cause a spectrum of pediatric encephalopathies with seizures, motor dysfunction, and developmental delay. Of the >80 distinct missense pathogenic variants, many appear to uniformly destabilize the guanine nucleotide handling of the mutant protein, speeding up GTP uptake and deactivating GTP hydrolysis. Zinc supplementation emerges as a promising treatment option for this disease, as Zn2+ ions reactivate the GTP hydrolysis on the mutant Gαo and restore cellular interactions for some of the mutants studied earlier. The molecular etiology of GNAO1 encephalopathies needs further elucidation as a prerequisite for the development of efficient therapeutic approaches. In this work, we combine clinical and medical genetics analysis of a novel GNAO1 mutation with an in-depth molecular dissection of the resultant protein variant. We identify two unrelated patients from Norway and France with a previously unknown mutation in GNAO1, c.509C>G that results in the production of the Pro170Arg mutant Gαo, leading to severe developmental and epileptic encephalopathy. Molecular investigations of Pro170Arg identify this mutant as a unique representative of the pathogenic variants. Its 100-fold-accelerated GTP uptake is not accompanied by a loss in GTP hydrolysis; Zn2+ ions induce a previously unseen effect on the mutant, forcing it to lose the bound GTP. Our work combining clinical and molecular analyses discovers a novel, biochemically distinct pathogenic missense variant of GNAO1 laying the ground for personalized treatment development.
Open AccessClinical Cases and the Molecular Profiling of a Novel Childhood Encephalopathy-Causing GNAO1 Mutation P170R
De novo mutations in GNAO1, the gene encoding the major neuronal G protein Gαo, cause a spectrum of pediatric encephalopathies with seizures, motor dysfunction, and developmental delay. Of the >80 distinct missense pathogenic variants, many appear to uniformly destabilize the guanine nucleotide handling of the mutant protein, speeding up GTP uptake and deactivating GTP hydrolysis. Zinc supplementation emerges as a promising treatment option for this disease, as Zn2+ ions reactivate the GTP hydrolysis on the mutant Gαo and restore cellular interactions for some of the mutants studied earlier. The molecular etiology of GNAO1 encephalopathies needs further elucidation as a prerequisite for the development of efficient therapeutic approaches. In this work, we combine clinical and medical genetics analysis of a novel GNAO1 mutation with an in-depth molecular dissection of the resultant protein variant. We identify two unrelated patients from Norway and France with a previously unknown mutation in GNAO1, c.509C>G that results in the production of the Pro170Arg mutant Gαo, leading to severe developmental and epileptic encephalopathy. Molecular investigations of Pro170Arg identify this mutant as a unique representative of the pathogenic variants. Its 100-fold-accelerated GTP uptake is not accompanied by a loss in GTP hydrolysis; Zn2+ ions induce a previously unseen effect on the mutant, forcing it to lose the bound GTP. Our work combining clinical and molecular analyses discovers a novel, biochemically distinct pathogenic missense variant of GNAO1 laying the ground for personalized treatment development.
- Top Cited PapersOpen Access
Molecular and clinical descriptions of patients with GABAA receptor gene variants (GABRA1, GABRB2, GABRB3, GABRG2): A cohort study, review of literature, and genotype–phenotype correlation
Objective: γ‐Aminobutyric acid (GABA)A‐receptor subunit variants have recently been associated with neurodevelopmental disorders and/or epilepsy. The phenotype linked with each gene is becoming better known. Because of the common molecular structure and physiological role of these phenotypes, it seemed interesting to describe a putative phenotype associated with GABAA‐receptor–related disorders as a whole and seek possible genotype–phenotype correlations.Methods: We collected clinical, electrophysiological, therapeutic, and molecular data from patients with GABAA‐receptor subunit variants (GABRA1, GABRB2, GABRB3, and GABRG2) through a national French collaboration using the EPIGENE network and compared these data to the one already described in the literature.Results: We gathered the reported patients in three epileptic phenotypes: 15 patients with fever‐related epilepsy (40%), 11 with early developmental epileptic encephalopathy (30%), 10 with generalized epilepsy spectrum (27%), and 1 patient without seizures (3%). We did not find a specific phenotype for any gene, but we showed that the location of variants on the transmembrane (TM) segment was associated with a more severe phenotype, irrespective of the GABAA‐receptor subunit gene, whereas N‐terminal variants seemed to be related to milder phenotypes.Significance: GABAA‐receptor subunit variants are associated with highly variable phenotypes despite their molecular and physiological proximity. None of the genes described here was associated with a specific phenotype. On the other hand, it appears that the location of the variant on the protein may be a marker of severity. Variant location may have important weight in the development of targeted therapeutics.
Top Cited PapersOpen AccessMolecular and clinical descriptions of patients with GABAA receptor gene variants (GABRA1, GABRB2, GABRB3, GABRG2): A cohort study, review of literature, and genotype–phenotype correlation
Objective: γ‐Aminobutyric acid (GABA)A‐receptor subunit variants have recently been associated with neurodevelopmental disorders and/or epilepsy. The phenotype linked with each gene is becoming better known. Because of the common molecular structure and physiological role of these phenotypes, it seemed interesting to describe a putative phenotype associated with GABAA‐receptor–related disorders as a whole and seek possible genotype–phenotype correlations.Methods: We collected clinical, electrophysiological, therapeutic, and molecular data from patients with GABAA‐receptor subunit variants (GABRA1, GABRB2, GABRB3, and GABRG2) through a national French collaboration using the EPIGENE network and compared these data to the one already described in the literature.Results: We gathered the reported patients in three epileptic phenotypes: 15 patients with fever‐related epilepsy (40%), 11 with early developmental epileptic encephalopathy (30%), 10 with generalized epilepsy spectrum (27%), and 1 patient without seizures (3%). We did not find a specific phenotype for any gene, but we showed that the location of variants on the transmembrane (TM) segment was associated with a more severe phenotype, irrespective of the GABAA‐receptor subunit gene, whereas N‐terminal variants seemed to be related to milder phenotypes.Significance: GABAA‐receptor subunit variants are associated with highly variable phenotypes despite their molecular and physiological proximity. None of the genes described here was associated with a specific phenotype. On the other hand, it appears that the location of the variant on the protein may be a marker of severity. Variant location may have important weight in the development of targeted therapeutics.